Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Merck (NYSE:MRK) is set to report its third-quarter earnings on Thursday, October 30, before the market opens. Consensus ...

Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same ...

MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.

Since the market sees this event as broadly positive for pharmaceutical companies, ABBV's stock has risen significantly.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access . * Reflecting concerns, ...

Merck's two most important growth drivers are encountering headwinds now. While they are manageable, the company's mid-term prospects aren't strong. Merck's biggest growth drivers are cancer drug ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...